Safety of Same-Day Pegfilgrastim Administration in Metastatic Castration-Resistant Prostate Cancer Treated With Cabazitaxel With Or Without Carboplatin

INTRODUCTION: Although myeloid growth factors are commonly used to treat metastatic castration-resistant prostate cancer (mCRPC), the optimal timing of administration has not been well studied. We assessed the effects of same-day pegfilgrastim, a neutrophil stimulator, after cabazitaxel treatment wi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Genitourin Cancer
Autors principals: Bilen, Mehmet Asim, Cauley, Diana H., Atkinson, Bradley J., Chen, Hsiang-Chun, Kaya, Diana H., Wang, Xuemei, Vikram, Raghu, Tu, Shi-Ming, Corn, Paul G., Kim, Jeri
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5446270/
https://ncbi.nlm.nih.gov/pubmed/28038931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2016.12.003
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars